Navigation Links
Sangamo BioSciences Announces Presentation At The 25th Annual Piper Jaffray Healthcare Conference
Date:11/25/2013

RICHMOND, Calif., Nov. 25, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 8:00 am ET on Wednesday, December 4, 2013, at the 25th Annual Piper Jaffray Healthcare Conference, which will be held in New York City.

(Logo:  http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 and Phase1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. As part of its acquisition of Ceregene Inc., Sangamo acquired a fully-enrolled and funded, double-blind, placebo-controlled Phase 2 trial to evaluate NGF-AAV (CERE-110) in Alzheimer's disease. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.    Sangamo has entered into a strategic collaboration with Shire to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciencesand Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

 


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
2. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
3. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
4. Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
5. Sangamo BioSciences Reports First Quarter 2012 Financial Results
6. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
7. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
8. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
9. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
10. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
11. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016  Dovetail Genomics™ LLC ... its beta program for a planned metagenomic genome assembly ... the company,s metagenomic genome assembly method in a talk ... Genome Biology & Technology conference in Orlando, ... these highly complex datasets is difficult. Using its proprietary ...
(Date:2/11/2016)... ... February 11, 2016 , ... Global ... treatment clinic in Quito, Ecuador. The new facility will provide advanced protocols and ... from around the world. , The new GSCG clinic is headed by ...
(Date:2/10/2016)... is introducing a hybrid membership model which will provide ... joining or renewing through an organizational purchasing model. For ... employee in any size association or AMC office can ... benefits.   John H. Graham, IV , ... organizations of any size and their employees to gain ...
(Date:2/10/2016)... Texas (PRWEB) , ... February 10, 2016 , ... ... centers across three states, announced today the promotion of two long-standing principal investigators ... Chief of Family Medicine, Clinical Research and Development. , Dr. Laurence Chu, a ...
Breaking Biology Technology:
(Date:1/22/2016)... 2016 http://www.researchandmarkets.com/research/p74whf/global_biometrics ... "Global Biometrics Market in Retail Sector ... --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has announced ... Market in Retail Sector 2016-2020" report ... Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has ...
(Date:1/20/2016)... , Jan. 20, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... significant achievements are the result of the company,s laser ... iMedNet eClinical , it,s comprehensive, easy-to-use and highly ... --> Key MedNet growth achievements in 2015 ...
(Date:1/15/2016)... SAN JUAN, Puerto Rico , Jan. 15, 2016 ... forcing companies big and small to find new ways ... data driven culture. iOS and ... their device based on biometrics, transforming it into a ... can request that users swipe their fingerprint on their ...
Breaking Biology News(10 mins):